Literature DB >> 8650886

Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine.

R Virag1, D Bachir, K Lee, F Galacteros.   

Abstract

OBJECTIVES: Priapism is a common and currently unsatisfactorily managed complication of sickle cell disease (SCD). In June 1994, 6 SCD patients received a new therapeutic regimen to prevent the occurrence and recurrence of priapism.
METHODS: The patients (5 with SS and 1 with SC) were adults and had frequent episodes of stuttering priapism (SP), and two of them had had acute episodes (AP) lasting more than 3 hours. The treatment consists of preventive oral administration of the alpha-adrenergic agent etilefrine, and self-administered intracavernous injection (SICI) of the same agent to reverse episodes lasting more than 1 hour.
RESULTS: Since the beginning of treatment, all patients were protected against AP, 4 patients had no recurrence with the oral treatment alone, 2 had to use SICI, 1 occasionally and 1 constantly. There was no modification of sexual activity and no complications. Blood pressure was unaffected.
CONCLUSIONS: This treatment is simple, cheap, and self-administered. It should be proposed to all patients with SCD in all geographic areas as part of an educational program for active prevention of this severe complication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8650886     DOI: 10.1016/s0090-4295(96)00027-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

1.  Management of sickle cell priapism with etilefrine.

Authors:  A D Gbadoé; Y Atakouma; K Kusiaku; J K Assimadi
Journal:  Arch Dis Child       Date:  2001-07       Impact factor: 3.791

Review 2.  Recent advances in the medical and surgical treatment of priapism.

Authors:  Adam Shrewsberry; Aaron Weiss; Chad W M Ritenour
Journal:  Curr Urol Rep       Date:  2010-11       Impact factor: 3.092

Review 3.  Medical management of ischemic stuttering priapism: a contemporary review of the literature.

Authors:  Helen R Levey; Omer Kutlu; Trinity J Bivalacqua
Journal:  Asian J Androl       Date:  2011-11-07       Impact factor: 3.285

Review 4.  Treatments for priapism in boys and men with sickle cell disease.

Authors:  Francis I Chinegwundoh; Sherie Smith; Kofi A Anie
Journal:  Cochrane Database Syst Rev       Date:  2017-09-19

Review 5.  Contemporary best practice in the evaluation and management of stuttering priapism.

Authors:  Georgios Kousournas; Asif Muneer; David Ralph; Evangelos Zacharakis
Journal:  Ther Adv Urol       Date:  2017-07-04

Review 6.  Priapism in hematological and coagulative disorders: an update.

Authors:  Belinda F Morrison; Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2011-03-15       Impact factor: 14.432

7.  Hemolysis-associated priapism in sickle cell disease.

Authors:  Vikki G Nolan; Diego F Wyszynski; Lindsay A Farrer; Martin H Steinberg
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

Review 8.  What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel.

Authors:  S Minhas; A Salonia; M Gül; B Luca; K Dimitropoulos; P Capogrosso; U Milenkovic; A Cocci; R Veeratterapillay; G Hatzichristodoulou; V Modgil; G I Russo; T Tharakan; A Kalkanli; M I Omar; C Bettocchi; J Carvalho; G Corona; T H Jones; A Kadioglu; J I Martinez-Salamanca; E C Serefoglu; P Verze
Journal:  Int J Impot Res       Date:  2022-08-08       Impact factor: 2.408

9.  Priapism in sickle cell anemia: emerging mechanistic understanding and better preventative strategies.

Authors:  Genevieve M Crane; Nelson E Bennett
Journal:  Anemia       Date:  2010-11-30

10.  Treatments for priapism in boys and men with sickle cell disease.

Authors:  Francis I Chinegwundoh; Sherie Smith; Kofi A Anie
Journal:  Cochrane Database Syst Rev       Date:  2020-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.